OOIR: Observatory of International Research

Papers

(The TQCC of Thoracic Cancer is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Curcumin induces ferroptosis in non‐small‐cell lung cancer via activating autophagy	109
Quercetin induces pro‐apoptotic autophagy via SIRT1/AMPK signaling pathway in human lung cancer cell lines A549 and H1299 in vitro	76
Epidemiology of esophageal cancer in 2020 and projections to 2030 and 2040	46
Circ‐RNF111 contributes to paclitaxel resistance in breast cancer by elevating E2F3 expression via miR‐140‐5p	46
LncRNA HOTAIR enhances breast cancer radioresistance through facilitating HSPA1A expression via sequestering miR‐449b‐5p	44
Switching administration of anti‐PD‐1 and anti‐PD‐L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non‐small cell lung cancer: Case series an	44
Meta‐analysis of immune‐related adverse events of immune checkpoint inhibitor therapy in cancer patients	42
Genomic characteristics and drug screening among organoids derived from non‐small cell lung cancer patients	40
Immune microenvironment features and efficacy of PD‐1/PD‐L1 blockade in non‐small cell lung cancer patients with EGFR or HER2 exon 20 insertions	39
Circular RNA CirCHIPK3 promotes cell proliferation and invasion of breast cancer by sponging miR‐193a/HMGB1/PI3K/AKT axis	39
CDK4/6 inhibitor palbociclib overcomes acquired resistance to third‐generation EGFR inhibitor osimertinib in non‐small cell lung cancer (NSCLC)	36
Expression and role of p16 and GLUT1 in malignant diseases and lung cancer: A review	33
Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non‐small cell lung cancer treated with anti‐PD‐1 antibody	32
circ_0007385 served as competing endogenous RNA for miR‐519d‐3p to suppress malignant behaviors and cisplatin resistance of non‐small cell lung cancer cells	32
Impact of COVID‐19 pandemic on lung cancer treatment scheduling	31
miR‐21‐5p/SMAD7 axis promotes the progress of lung cancer	31
Metagenome association study of the gut microbiome revealed biomarkers linked to chemotherapy outcomes in locally advanced and advanced lung cancer	31
Propofol suppresses lung cancer tumorigenesis by modulating the circ‐ERBB2/miR‐7‐5p/FOXM1 axis	30
Smoking status during first‐line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study	28
Tumor‐associated macrophages: An important player in breast cancer progression	28
Global burden of thyroid cancer and its attributable risk factors in 204 countries and territories from 1990 to 2019	27
Serum exosomal miR‐1269a serves as a diagnostic marker and plays an oncogenic role in non‐small cell lung cancer	27
Exosome‐derived miR‐210 involved in resistance to osimertinib and epithelial–mesenchymal transition in EGFR mutant non‐small cell lung cancer cells	27
Outcome and risk factor of immune‐related adverse events and pneumonitis in patients with advanced or postoperative recurrent non‐small cell lung cancer treated with immune checkpoint inhibitors	27
Impact of concomitant medication on clinical outcomes in patients with advanced non‐small cell lung cancer treated with immune checkpoint inhibitors: A retrospective study	26

CAR‐T cell therapy for lung cancer: Potential and perspective	25
Adverse impact of bone metastases on clinical outcomes of patients with advanced non‐small cell lung cancer treated with immune checkpoint inhibitors	24
Circ_0072088 promotes the development of non‐small cell lung cancer via the miR‐377‐5p/NOVA2 axis	24
Tumor‐educated platelet SNORD55 as a potential biomarker for the early diagnosis of non‐small cell lung cancer	23
MiR‐429 suppresses proliferation and invasion of breast cancer via inhibiting the Wnt/β‐catenin signaling pathway	23
Survival and pretreatment prognostic factors for extensive‐stage small cell lung cancer: A comprehensive analysis of 358 patients	23
KIF4A enhanced cell proliferation and migration via Hippo signaling and predicted a poor prognosis in esophageal squamous cell carcinoma	23
Biglycan, tumor endothelial cell secreting proteoglycan, as possible biomarker for lung cancer	22
Robot‐assisted thoracic surgery versus video‐assisted thoracic surgery for treatment of patients with thymoma: A systematic review and meta‐analysis	22
GPX8 promotes migration and invasion by regulating epithelial characteristics in non‐small cell lung cancer	22
Identifying sarcopenia in advanced non‐small cell lung cancer patients using skeletal muscle CT radiomics and machine learning	21
Osimertinib combined with bevacizumab for leptomeningeal metastasis from EGFR‐mutation non‐small cell lung cancer: A phase II single‐arm prospective clinical trial	21
Targeting the EMT transcription factor Snail overcomes resistance to osimertinib in EGFR‐mutant non‐small cell lung cancer	21
LncRNASGMS1‐AS1 regulates lung adenocarcinoma cell proliferation, migration, invasion, and EMT progression via miR‐106a‐5p/MYLI9 axis	21
Clinical implication of minimal presence of solid or micropapillary subtype in early‐stage lung adenocarcinoma	21
Plasma miR‐1247‐5p, miR‐301b‐3p and miR‐105‐5p as potential biomarkers for early diagnosis of non‐small cell lung cancer	20
PIWI‐interacting RNAs are aberrantly expressed and may serve as novel biomarkers for diagnosis of lung adenocarcinoma	20
Downregulation of m⁶A reader YTHDC2 promotes tumor progression and predicts poor prognosis in non‐small cell lung cancer	20
Tumor‐associated macrophages (TAMs)‐derived osteopontin (OPN) upregulates PD‐L1 expression and predicts poor prognosis in non‐small cell lung cancer (NSCLC)	20
Exosomal miR‐3180‐3p inhibits proliferation and metastasis of non‐small cell lung cancer by downregulating FOXP4	19
Role of endothelin receptor type B (EDNRB) in lung adenocarcinoma	19
tRNA‐derived fragments: tRF‐Gly‐CCC‐046, tRF‐Tyr‐GTA‐010 and tRF‐Pro‐TGG‐001 as novel diagnostic biomarkers for breast cancer	19
Spread through air spaces (STAS) in invasive mucinous adenocarcinoma of the lung: Incidence, prognostic impact, and prediction based on clinicoradiologic factors	19
Clinical utility of the C‐reactive protein:albumin ratio in non‐small cell lung cancer patients treated with nivolumab	19
Circulating cytokines associated with clinical outcomes in advanced non‐small cell lung cancer patients who received chemoimmunotherapy	18
Association between pretreatment neutrophil‐to‐lymphocyte ratio and immune‐related adverse events due to immune checkpoint inhibitors in patients with non‐small cell lung cancer	18
Efficacy and safety of PD‐1/PD‐L1 inhibitor plus chemotherapy versus chemotherapy alone as first‐line treatment for extensive‐stage small cell lung cancer: A systematic review and meta‐analysis	18
LncRNA LINC00460: Function and mechanism in human cancer	18
Prognostic factor analysis of patients with small cell lung cancer: Real‐world data from 988 patients	18
Feasibility of next‐generation sequencing test for patients with advanced NSCLC in clinical practice	18
A novel lncRNA‐miRNA‐mRNA competing endogenous RNA regulatory network in lung adenocarcinoma and kidney renal papillary cell carcinoma	18
Immune checkpoint inhibitor‐related adverse events in lung cancer: Real‐world incidence and management practices of 1905 patients in China	18
LncRNA FAM83A‐AS1 promotes lung adenocarcinoma progression by enhancing the pre‐mRNA stability of FAM83A	18
microRNA‐100 functions as a tumor suppressor in non‐small cell lung cancer via regulating epithelial‐mesenchymal transition and Wnt/β‐catenin by targeting HOXA1	18
Anti‐PD1 versus anti‐PD‐L1 immunotherapy in first‐line therapy for advanced non‐small cell lung cancer: A systematic review and meta‐analysis	18
Lung cancer risk prediction models based on pulmonary nodules: A systematic review	17
Predictors of survival among Japanese patients receiving first‐line chemoimmunotherapy for advanced non‐small cell lung cancer	17
Clinical effect of bronchial arterial infusion chemotherapy and CalliSpheres drug‐eluting beads in patients with stage II–IV lung cancer: A prospective cohort study	17
Safety and effectiveness of pirfenidone combined with carboplatin‐based chemotherapy in patients with idiopathic pulmonary fibrosis and non‐small cell lung cancer: A retrospective cohort study	17
Immunotherapy as second‐line treatment and beyond for non‐small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a real‐world retrospective anal	17
Identification of a novel anoikis‐related gene signature to predict prognosis and tumor microenvironment in lung adenocarcinoma	17
Anlotinib can overcome acquired resistance to EGFR‐TKIs via FGFR1 signaling in non‐small cell lung cancer without harboring EGFR T790M mutation	17
Comprehensive genomic profiling of Brazilian non‐small cell lung cancer patients (GBOT 0118/LACOG0418)	17
Differential diagnosis of lung cancer and benign lung lesion using salivary metabolites: A preliminary study	17
Prognostic factors for survival in patients with metastatic lung adenocarcinoma: An analysis of the SEER database	17
Identification of small proline‐rich protein 1B (SPRR1B) as a prognostically predictive biomarker for lung adenocarcinoma by integrative bioinformatic analysis	17
Novel long non‐coding RNA LINC02323 promotes epithelial‐mesenchymal transition and metastasis via sponging miR‐1343‐3p in lung adenocarcinoma	17
Prognostic value of the geriatric nutritional risk index among patients with previously treated advanced non‐small cell lung cancer who subsequently underwent immunotherapy	17
Clinical outcomes and radiation pneumonitis after concurrent EGFR‐tyrosine kinase inhibitors and radiotherapy for unresectable stage III non‐small cell lung cancer	17
MiR‐205‐5p promotes lung cancer progression and is valuable for the diagnosis of lung cancer	16

Prediction model for hyperprogressive disease in non‐small cell lung cancer treated with immune checkpoint inhibitors	16
Real‐world efficacy of atezolizumab in non‐small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti‐PD‐1 antibody	16
Genomic characteristics of driver genes in Chinese patients with non‐small cell lung cancer	16
Overexpression of hsa_circ_0008274 inhibited the progression of lung adenocarcinoma by regulating HMGA2 via sponging miR‐578	16
Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG‐LU16‐07	16
CAPN1 promotes malignant behavior and erlotinib resistance mediated by phosphorylation of c‐Met and PIK3R2via degrading PTPN1 in lung adenocarcinoma	16
Electromagnetic navigation bronchoscopic localization versus percutaneous CT‐guided localization for thoracoscopic resection of small pulmonary nodules	16
Association between serum biomarkers CEA and LDH and response in advanced non‐small cell lung cancer patients treated with platinum‐based chemotherapy	15
Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced non‐small cell lung cancer in comparison with chemoradiotherapy alone	15
Characteristics of surgically resected non‐small cell lung cancer patients with post‐recurrence cure	15
MiR‐133a acts as a tumor suppressor in lung cancer progression by regulating the LASP1 and TGF‐β/Smad3 signaling pathway	15
Long non‐coding RNA HCG11 sponging miR‐522‐3p inhibits the tumorigenesis of non‐small cell lung cancer by upregulating SOCS5	15
Invasive mucinous adenocarcinoma of the lung: Serial CT findings, clinical features, and treatment and survival outcomes	15
Clinical characteristics and risk factors for in‐hospital mortality of lung cancer patients with COVID‐19: A multicenter, retrospective, cohort study	15
Upregulation of lncRNA ZFAS1 promotes lung adenocarcinoma progression by sponging miR‐1271‐5p and upregulating FRS2	15
Pre‐existing interstitial lung disease does not affect prognosis in non‐small cell lung cancer patients with PD‐L1 expression ≥50% on first‐line pembrolizumab	15
Liquid biopsies to distinguish malignant from benign pulmonary nodules	15
Circulating microRNAs as indicators in the prediction of neoadjuvant chemotherapy response in luminal B breast cancer	15
Propofol suppresses hypoxia‐induced esophageal cancer cell migration, invasion, and EMT through regulating lncRNA TMPO‐AS1/miR‐498 axis	14
LINC00662 promotes cell viability and metastasis in esophageal squamous cell carcinoma by sponging miR‐340‐5p and upregulating HOXB2	14
ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non‐small cell lung cancer	14
Impacts of post‐radiotherapy lymphocyte count on progression‐free and overall survival in patients with stage III lung cancer	14
Autologous cytokine‐induced killer (CIK) cells enhance the clinical response to PD‐1 blocking antibodies in patients with advanced non‐small cell lung cancer: A preliminary study	14
LncRNA LINC00511 plays an oncogenic role in lung adenocarcinoma by regulating PKM2 expression via sponging miR‐625‐5p	14
Clinicopathological characteristics of primary lung nuclear protein in testis carcinoma: A single‐institute experience of 10 cases	14
Comparative study of clinicopathological characteristics and prognosis between combined and pure small cell lung cancer (SCLC) after surgical resection	14
Short‐term local control after VATS segmentectomy and lobectomy for solid NSCLC of less than 2 cm	14
Comparison of adequacy between transbronchial lung cryobiopsy samples and endobronchial ultrasound‐guided transbronchial needle aspiration samples for next‐generation sequencing analysis	14
Ultrathin bronchoscope combined with virtual bronchoscopic navigation and endobronchial ultrasound for the diagnosis of peripheral pulmonary lesions with or without fluoroscopy: A randomized trial	14
Hsa_circRNA_0000518 facilitates breast cancer development via regulation of the miR‐326/FGFR1 axis	14
Activity of tarloxotinib‐E in cells with EGFR exon‐20 insertion mutations and mechanisms of acquired resistance	14
Quantitative multiplex immunofluorescence analysis identifies infiltrating PD1⁺CD8⁺ and CD8⁺ T cells as predictive of response to neoadjuvant chemotherapy i	13
Mediastinal “deep freeze”—transcarinal lymph node cryobiopsy	13
HSP90 inhibition overcomes EGFR amplification‐induced resistance to third‐generation EGFR‐TKIs	13
Increased activation of cGAS‐STING pathway enhances radiosensitivity of non‐small cell lung cancer cells	13
SHR‐1316, an anti‐PD‐L1 antibody, plus chemotherapy as the first‐line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase 2 study	13
HAX1 enhances the survival and metastasis of non‐small cell lung cancer through the AKT/mTOR and MDM2/p53 signaling pathway	13
Use of glucocorticoids in the management of immunotherapy‐related adverse effects	13
Efficacy and safety of anti‐PD‐1/PD‐L1 in combination with chemotherapy or not as first‐line treatment for advanced non‐small cell lung cancer: A systematic review and network me	13
High expression of KITLG is a new hallmark activating the MAPK pathway in type A and AB thymoma	13
The landscape of small cell lung cancer metastases: Organ specificity and timing	13
Microwave ablation via a flexible catheter for the treatment of nonsurgical peripheral lung cancer: A pilot study	13
Long‐term survivor of pulmonary combined large cell neuroendocrine carcinoma treated with nivolumab	13
Clinical recommendations on lung cancer management during the COVID‐19 pandemic	13
MicroRNA‐200b is a potential biomarker of the expression of PD‐L1 in patients with lung cancer	12
Prediction of tumor doubling time of lung adenocarcinoma using radiomic margin characteristics	12
Small cell transformation of non‐small cell lung cancer under immunotherapy: Case series and literature review	12
Bevacizumab plus chemotherapy in nonsquamous non‐small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Ja	12
Tumor invasion in the central airway is a risk factor for early‐onset checkpoint inhibitor pneumonitis in patients with non‐small cell lung cancer	12
Prognostic impact of micropapillary component in patients with node‐negative subcentimeter lung adenocarcinoma: A Chinese cohort study	12
Influence of adjuvant chemotherapy on survival for patients with stage IB and IIA non‐small cell lung cancer	12
Two cases of lung cancer with hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors	12
Evaluation of dual‐energy and perfusion CT parameters for diagnosing solitary pulmonary nodules	12
Silencing LINC01116 suppresses the development of lung adenocarcinoma via the AKT signaling pathway	12
Lung‐specific exosomes for co‐delivery of CD47 blockade and cisplatin for the treatment of non–small cell lung cancer	12
M2 macrophages reduce the effect of gefitinib by activating AKT/mTOR in gefitinib‐resistant cell lines HCC827/GR	12
Clinical outcomes and resource utilization after surgical resection with curative intent among patients with non‐small cell lung cancer treated with adjuvant therapies in a community oncology setting:	12
MiR‐423‐5p aggravates lung adenocarcinoma via targeting CADM1	12
Progesterone/Org inhibits lung adenocarcinoma cell growth via membrane progesterone receptor alpha	12
Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small‐cell lung cancer patients treated with first‐line platinum‐containing chemotherapy	12
Efficacy of natural killer cell activity as a biomarker for predicting immunotherapy response in non‐small cell lung cancer	12
Circular RNA circCPA4 promotes tumorigenesis by regulating miR‐214‐3p/TGIF2 in lung cancer	12
Reproducible abscopal effect in a patient with lung cancer who underwent whole‐brain irradiation and atezolizumab administration	12
Association of CD8 T cell apoptosis and EGFR mutation in non‐small lung cancer patients	12
Exosomal circDNER enhances paclitaxel resistance and tumorigenicity of lung cancer via targeting miR‐139‐5p/ITGB8	12
Aspirin overcomes cisplatin resistance in lung cancer by inhibiting cancer cell stemness	12
miR‐223‐3p targets FBXW7 to promote epithelial‐mesenchymal transition and metastasis in breast cancer	12
Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases	12
Oncological advantage of nonintubated thoracic surgery: Better compliance of adjuvant treatment after lung lobectomy	11
MiR‐192/NKRF axis confers lung cancer cell chemoresistance to cisplatin via the NF‐κB pathway	11
Tissue surface area and tumor cell count affect the success rate of the Oncomine Dx Target Test in the analysis of biopsy tissue samples	11
Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation	11
Construction of PEI‐EGFR‐PD‐L1‐siRNA dual functional nano‐vaccine and therapeutic efficacy evaluation for lung cancer	11
Feasibility investigation of near‐infrared fluorescence imaging with intravenous indocyanine green method in uniport video‐assisted thoracoscopic anatomical segmentectomy for identifying the intersegm	11
GRP75‐mediated upregulation of HMGA1 stimulates stage I lung adenocarcinoma progression by activating JNK/c‐JUN signaling	11
Progress in three‐dimensional computed tomography reconstruction in anatomic pulmonary segmentectomy	11
Circ_0000520 contributes to triple‐negative breast cancer progression through mediating the miR‐1296/ZFX axis	11
Surgical perspective in neoadjuvant chemoimmunotherapy for stage II–III non‐small cell lung cancer	11
CT‐guided microwave ablation in patients with lung metastases from breast cancer	11
Circ_ZFR affects FABP7 expression to regulate breast cancer progression by acting as a sponge for miR‐223‐3p	11

Detection of circulating genetically abnormal cells in peripheral blood for early diagnosis of non‐small cell lung cancer	11
PD‐L1 and CD47 co‐expression predicts survival and enlightens future dual‐targeting immunotherapy in non‐small cell lung cancer	11
Estimated direct costs of non‐small cell lung cancer by stage at diagnosis and disease management phase: A whole‐disease model	11
Inflammation‐nutritional markers of peripheral blood could predict survival in advanced non‐small‐cell lung cancer patients treated with PD‐1 inhibitors	11
The airway microbiota of non‐small cell lung cancer patients and its relationship to tumor stage andEGFRgene mutation	11
Prognostic value of ferroptosis‐related genes in patients with lung adenocarcinoma	11
Surgical outcomes of 215 patients with thymic epithelial tumors: A single‐center experience	11
ALK‐rearranged squamous cell carcinoma of the lung	11
Autologous blood pleurodesis for the treatment of postoperative air leaks. A systematic review and meta‐analysis	11
Lung adenocarcinoma patients with KEAP1 mutation harboring low immune cell infiltration and low activity of immune environment	11
TMEM107 inhibits EMT and invasion of NSCLC through regulating the Hedgehog pathway	11
Remarkable response to pembrolizumab with platinum‐doublet in PD‐L1‐low pulmonary sarcomatoid carcinoma: A case report	11
Circulating tumor cells (CTCs)/circulating tumor endothelial cells (CTECs) and their subtypes in small cell lung cancer: Predictors for response and prognosis	11
Efficacy of PD‐1/PD‐L1 inhibitors in patients with non‐small cell lung cancer and brain metastases: A real‐world retrospective study in China	11
Thymoma‐associated myasthenia gravis: Clinical features and predictive value of antiacetylcholine receptor antibodies in the risk of recurrence of thymoma	11
Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non‐small cell lung cancer (AB‐CLICaP)	11
The LungVision navigational platform for peripheral lung nodule biopsy and the added value of cryobiopsy	11
Transformation from adenocarcinoma to squamous cell lung carcinoma with MET amplification after lorlatinib resistance: A case report	11
Clinical‐radiological characteristics and intestinal microbiota in patients with pancreatic immune‐related adverse events	11
Matrix metalloproteinase‐14 (MMP‐14) downregulation inhibits esophageal squamous cell carcinoma cell migration, invasion, and proliferation	11
Combination treatment with artemisinin and oxaliplatin inhibits tumorigenesis in esophageal cancer EC109 cell through Wnt/β‐catenin signaling pathway	10
Resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer patients: A meta‐analysis	10
Hexokinases II‐mediated glycolysis governs susceptibility to crizotinib in ALK‐positive non‐small cell lung cancer	10
The prognostic significance of tumor spread through air space in stage I lung adenocarcinoma	10
The role of EGFR‐TKIs as adjuvant therapy in EGFR mutation‐positive early‐stage NSCLC: A meta‐analysis	10
Impact of interstitial lung disease and simultaneous lung cancer on therapeutic possibilities and survival	10
Pembrolizumab provides long‐term survival benefits in advanced non‐small cell lung cancer: The 5‐year outcomes of the KEYNOTE‐024 trial	10
Formation, contents, functions of exosomes and their potential in lung cancer diagnostics and therapeutics	10
Real‐world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non‐small cell lung cancer	10
Use of PD‐1 inhibitor tislelizumab in the treatment of advanced pulmonary sarcomatoid carcinoma: A case report	10
Effects of avitinib on the pharmacokinetics of osimertinib in vitro and in vivo in rats	10
Intraoperative diagnosis of lymph node metastasis during segmentectomy for non‐small cell lung cancer by rapid immunohistochemistry using noncontact alternating current electric field mixing	10
Inhibitors of ABCB1 and ABCG2 overcame resistance to topoisomerase inhibitors in small cell lung cancer	10
Successful treatment of pyrotinib for bone marrow metastasis induced pancytopenia in a patient with non‐small‐cell lung cancer and ERBB2 mutation	10
Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non‐small cell lung cancer receiving EGFR‐TKI treatment	10
Elevations of monocyte and neutrophils, and higher levels of granulocyte colony‐stimulating factor in peripheral blood in lung cancer patients	10
Comparison of the analytical performance between the Oncomine Dx Target Test and a conventional single gene test for epidermal growth factor receptor mutati	10
lncRNAs classifier to accurately predict the recurrence of thymic epithelial tumors	10
Immune checkpoint inhibitors for first‐line treatment of advanced non‐small‐cell lung cancer: A systematic review and network meta‐analysis	10
Successful use of extracorporeal membrane oxygenation for airway‐obstructing lung adenocarcinoma	10
BCAR1 promotes proliferation and cell growth in lung adenocarcinoma via upregulation of POLR2A	10
DLL3 expression is a predictive marker of sensitivity to adjuvant chemotherapy for pulmonary LCNEC	10
A fully automated noncontrast CT 3‐D reconstruction algorithm enabled accurate anatomical demonstration for lung segmentectomy	10
MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC	10
Remarkable response of non‐small cell lung cancer to nintedanib treatment in a patient with idiopathic pulmonary fibrosis	10
Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma	10
Fresh fruit consumption may decrease the long‐term risk of esophageal cancer mortality: A 30‐year follow‐up study in the Linxian Dysplasia Nutrition Intervention trial (NIT)	10
Comparison of ultrasound and mammography for early diagnosis of breast cancer among Chinese women with suspected breast lesions: A prospective trial	10
Chaperone‐mediated autophagy affects tumor cell proliferation and cisplatin resistance in esophageal squamous cell carcinoma	10
Interstitial lung disease associated with capmatinib therapy in a patient with non‐small cell lung cancer harboring a skipping mutation of MET exon 14	10
Dynamics of D‐dimer in non‐small cell lung cancer patients receiving radical surgery and its association with postoperative venous thromboembolism	10
RNF213 gene mutation in circulating tumor DNA detected by targeted next‐generation sequencing in the assisted discrimination of early‐stage lung cancer from pulmonary nodu	9
Mubritinib enhanced the inhibiting function of cisplatin in lung cancer by interfering with mitochondrial function	9
CEACAM6 promotes cisplatin resistance in lung adenocarcinoma and is regulated by microRNA‐146a and microRNA‐26a	9
Clinical characteristics and management of primary mediastinal cysts: A single‐center experience	9
Effectiveness of EGFR‐TKI rechallenge immediately after PD‐1 blockade failure	9
LncRNA SNHG20 promoted proliferation, invasion and inhibited cell apoptosis of lung adenocarcinoma via sponging miR‐342 and upregulating DDX49	9
Quantitative analysis of endobronchial ultrasound elastography in computed tomography‐negative mediastinal and hilar lymph nodes	9
Outcomes of salvage lung resections in advanced EGFR‐mutant lung adenocarcinomas under EGFR TKIs	9
Noninvasive assessment of breast cancer molecular subtypes on multiparametric MRI using convolutional neural network with transfer learning	9
Clinical evaluation of the effectiveness of fusion‐induced asymmetric transcription assay‐based reverse transcription droplet digital PCR for ALK detection in formalin‐fix	9
Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: A	9
A cross‐sectional study of psychological burden in Chinese patients with pulmonary nodules: Prevalence and impact on the management of nodules	9
Intestinal flora characteristics of advanced non‐small cell lung cancer in China and their role in chemotherapy based on metagenomics: A prospective exploratory cohort study	9
Susceptibility of lung cancer patients to COVID‐19: A review of the pandemic data from multiple nationalities	9
Efficacy and predictors of rechallenge with immune checkpoint inhibitors in non‐small cell lung cancer	9
miR‐493 by regulating of c‐Jun targets Wnt5a/PD‐L1‐inducing esophageal cancer cell development	9
Management of chyle leakage after general thoracic surgery: Impact of thoracic duct embolization	9
Outcomes of lobectomy on pulmonary function for early stage non‐small cell lung cancer (NSCLC) patients with chronic obstructive pulmonary disease (COPD)	9
Significant difference in recurrence according to the proportion of high grade patterns in stage IA lung adenocarcinoma	9
Three‐dimensional printed polyether‐ether‐ketone implant for extensive chest wall reconstruction: A case report	9
History and current situation of neoadjuvant treatment for locally advanced esophageal cancer	9
Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan	9
A retrospective stenting study on superior vena cava syndrome caused by lung cancer	9
Zinc‐finger E‐box‐binding homeobox 1 (ZEB1) plays a crucial role in the maintenance of lung cancer stem cells resistant to gefitinib	9
Preoperative predictors of restoration in quality of life after surgery for lung cancer	9
Long non‐coding RNA CCAT1 sponges miR‐490 to enhance cell proliferation and migration of non‐small cell lung cancer	9
Significance of tumor mutation burden and immune infiltration in thymic epithelial tumors	9
Recombinant human adenovirus type 5 (Oncorine) reverses resistance to immune checkpoint inhibitor in a patient with recurrent non‐small cell lung cancer: A case report	9
Diabetic ketoacidosis shortly after COVID‐19 vaccination in a non–small‐cell lung cancer patient receiving combination of PD‐1 and CTLA‐4 inhibitors: A case report	8
HN1L promotes invasion and metastasis of the esophagogastric junction adenocarcinoma	8
Scutellarin improves the radiosensitivity of non‐small cell lung cancer cells to iodine‐125 seeds via downregulating the AKT/mTOR pathway	8
Modified Collard versus end‐to‐side hand‐sewn anastomosis for cervical anastomosis after McKeown esophagectomy	8
Safety and efficacy of microwave ablation for lung cancer adjacent to the interlobar fissure	8
Longitudinal changes in skeletal muscle mass in patients with advanced squamous cell lung cancer	8
Learning curve of robotic portal lobectomy for pulmonary neoplasms: A prospective observational study	8
Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA	8
A phase II study of anlotinib combined with etoposide and platinum‐based regimens in the first‐line treatment of extensive‐stage small cell lung cancer	8
Clinical outcomes of EGFR+/METamp+ vs. EGFR+/METamp‐ untreated patients with advanced non‐small cell lung cancer	8
Simultaneous bilateral pulmonary resection via single‐utility port VATS for multiple pulmonary nodules: A single‐center experience of 16 cases	8
Treatment patterns and outcomes of immunotherapy in extensive‐stage small‐cell lung cancer based on real‐world practice	8
A targeted siRNA‐loaded PDL1‐exosome and functional evaluation against lung cancer	8
MicroRNA‐374b mediates the initiation of non‐small cell lung cancer by regulating ITGB1 and p53 expressions	8
Effect of cyclooxygenase inhibitor use on immunotherapy efficacy in non‐small cell lung cancer	8
Primary ciliated muconodular papillary tumor: A rare pulmonary disease and literature review of 65 cases	8